Unusual Presentations for EBV and HHV8 Co-Infections: A Case Report and Review of Literature

Authors

  • Elena Trevisani Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author
  • Alice Parisi Department of Diagnostics and Public Health, Section of Pathology, University Hospital of Verona, Verona, ITA Author
  • Isacco Ferrarini Department of Engineering for Innovation Medicine, Section of Hematology, University Hospital of Verona, Verona, ITA Author
  • Fulvia Mazzaferri Department of Diagnostics and Public Health, Section of Infectious Diseases, University Hospital of Verona, Verona, ITA Author
  • Michele Milella Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author
  • Silvia Nicolini Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author
  • Alice Rossi Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author
  • Irene Torresan Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author
  • Anna Reni Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author
  • Michele Borghesani Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author
  • Sara Cingarlini Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA Author

DOI:

https://doi.org/10.47363/JCCSR/2023(5)258

Keywords:

T cell lymphoproliferative disorder, autoimmune hemolytic anemia (AIHA), cytotoxic chemotherapy, HIV-negative Kaposi sarcoma, Epstein Barr virus (EBV), HHV 8

Abstract

HHV-8 is known to be related to Kaposi sarcomas but can be responsible for other diseases such as Castleman’s disease (MCD) and primary effusion lymphoma (PEL). Epstein-Barr virus, on the other hand, is generally responsible for B-lineage lymphoproliferative diseases (LPD). In this case report we describe the case of a co-infection with HHV-8 and EBV with an unusual presentation. It is in fact a Kaposi sarcoma diagnosed in a heterosexual, immunocompetent and HIV-negative patient who initially presented with nodal disease only and a severe hemolytic anaemia. The same patient was also diagnosed with a T-lineage LPD with only bone marrow localization. The overall clinical presentation evolved favorably until complete resolution with the use of chemotherapy including drugs active in both histotypes. These data are contextualized with the evidence available in the current literature regarding the most common clinical manifestations of these infections.

Categories: Infectious Disease, Oncology, Hematology Keywords: t cell lymphoproliferative disorder, autoimmune hemolytic anemia (aiha), cytotoxic chemotherapy, hiv negative kaposi sarcoma, epstein barr virus (EBV), hhv 8

Author Biographies

  • Elena Trevisani, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Elena Trevisani, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

  • Alice Parisi, Department of Diagnostics and Public Health, Section of Pathology, University Hospital of Verona, Verona, ITA

    Alice Parisi, Department of Diagnostics and Public Health, Section of Pathology, University Hospital of Verona, Verona, ITA

  • Isacco Ferrarini, Department of Engineering for Innovation Medicine, Section of Hematology, University Hospital of Verona, Verona, ITA

    Isacco Ferrarini, Department of Engineering for Innovation Medicine, Section of Hematology, University Hospital of Verona, Verona, ITA

  • Fulvia Mazzaferri, Department of Diagnostics and Public Health, Section of Infectious Diseases, University Hospital of Verona, Verona, ITA

    Fulvia Mazzaferri, Department of Diagnostics and Public Health, Section of Infectious Diseases, University Hospital of Verona, Verona, ITA

  • Michele Milella, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Michele Milella, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

  • Silvia Nicolini, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Silvia Nicolini, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

  • Alice Rossi, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Alice Rossi, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

  • Irene Torresan, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Irene Torresan, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

  • Anna Reni, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Anna Reni, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

  • Michele Borghesani , Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Michele Borghesani, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

  • Sara Cingarlini, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

    Sara Cingarlini, Department of Engineering for Innovation Medicine, Section of Oncology, University Hospital of Verona, Verona, ITA

Downloads

Published

2023-09-18